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a Safe and Durable Landing Zone
Gelpi G., Vanelli P., Mangini A., Danna P., Contino M., Antona C. Eur J
Vasc Endovasc Surg 2010;40:712-7.
Objectives: Hybrid aortic arch repair procedure was introduced to
reduce invasiveness in high-risk patients with aortic arch pathology. The
good results are expanding its application, but endoleak, particularly type I,
remains its Achilles’ heel.
Design: We describe our experience with hybrid treatment of aortic
arch diseases focussing on techniques and results to avoid type I endoleak.
Materials and Methods: A total of 15 high-risk patients with zone
0–2 aortic arch pathology underwent supra-aortic debranching on ascend-
ing aorta and proximal aortic arch reinforcement with a Dacron prosthesis.
Metachronously, the procedure was completed with endovascular stent
grafting (ESG).
Results: Median age was 70 years with a mean European System for
Cardiac Operative Risk Evaluation (EuroSCORE) of 12.7  6.8. One
patient died between aortic debranching and ESG. Mean time between
surgical debranching and ESG was 32  27.7 days. No major neurological
events occurred. Mean length of the landing zone for ESG was 3.8 
0.8 cm. Computed tomography (CT) angiography scan performed soon
after operation, and at 3, 6, and 12 months did not show any type I endoleak.
Conclusions: Supra-aortic debranching on ascending aorta with prox-
imal aortic arch reinforcement is a useful step to ensure a safe landing zone
for ESG, reducing risk early to midterm of endoleak. Longer term follow-up
is required to confirm the viability of this technique.
Hybrid Repair of the Aortic Arch in Patients with Extensive Aortic
Disease
Antoniou G.A., Mireskandari M., Bicknell C.D., Cheshire N.J.W., Gibbs
R.G., Hamady M., Wolfe J.H.N., Jenkins M.P. Eur J Vasc Endovasc Surg
2010;40:718-24.
Objective: To evaluate the outcome of hybrid treatment of the aortic
arch with supra-aortic debranching and endovascular stent-graft repair in a
selected group of patients with complex disease.
Design: Case series study with retrospective analysis of prospectively
collected non-randomised data.
Methods: Patients with hybrid repair of complex arch disease at a single
centre over a 6-year period were enrolled in the study. Only patients with
extensive arch pathologies requiring debranching of at least the left carotid
artery were considered. Patients were divided into those who underwent
complete and partial supra-aortic revascularisation. The 2 test was used to
evaluate differences in outcomes. Logistic regression analyses were applied
to identify predictors of poor outcome.
Results: A total of 33 patients were included in the study. Complete
and partial arch repair was performed in nine and 24 patients, respectively.
The aortic disease extended to the thoracic and abdominal aorta in 39% and
52% of the patients, respectively. One-third of the patients (30%) were
treated on an urgent/emergency basis. Elective 30-day mortality and mor-
bidity rates were 13% and 35%, respectively. Early mortality was significantly
higher in the complete arch repair group (p  0.046). Pre-existing renal
impairment was identified as a poor prognostic factor. All extra-anatomic
bypasses remained patent and no aortic disease-related deaths occurred
during a mean follow-up period of 23 months (range, 1.5–58 months).
Complete arch repair was associated with an increased incidence of late
endoleak (p  0.018).
Conclusions: Hybrid treatment of the aortic arch provides a feasible
alternative treatment in patients who are high risk for conventional open
surgical repair. Careful selection of patients is required to achieve satisfactory
results.
The Incidence of Spinal Cord Ischaemia Following Thoracic and
Thoracoabdominal Aortic Endovascular Intervention
Drinkwater S.L., Goebells A., Haydar A., Bourke P., Brown L., Hamady M.,
Gibbs R.G.J. On behalf of the Regional Vascular Unit, St Mary’s Hospital,
Imperial College NHS Trust. Eur J Vasc Endovasc Surg 2010;40:732-8.
Objectives: To determine the incidence and risk factors for spinal cord
ischaemia (SCI) following thoracic and thoracoabdominal aortic interven-
tion.Methods: A prospective database of all thoracic and thoracoabdominal
aortic interventions between 2001 and 2009 was used to investigate the
incidence of SCI. All elective and emergency cases for all indications were
included. Logistic regression was used to investigate which factors were
associated with SCI.
Results: 235 patients underwent thoracic aortic stent grafting; 111
(47%) thoracic aortic stent-grafts alone, with an additional 14 (6%) branched
or fenestrated thoracic grafts, 30 (13%) arch hybrid procedures and 80 (34%)
visceral hybrid surgical and endovascular procedures. The global incidence
of SCI for all procedures was 23/235 (9.8%) and this included emergency
indications (ruptured TAAA and acute complex dissections) but the inci-
dence varied considerably between types of procedures. Of the 23 cases,
death occurred in 4 patients but recovery of function was seen in 6. Thus,
permanent paraplegia occurred in 13/235 (5.5%) patients. Of the nine
pre-specified factors investigated for association with SCI, only percentage
of aortic coverage was significantly associated with the incidence of SCI;
adjusted odds ratio per 10% increase in aorta covered  1.78 [95% CI
1.18–2.71], p 0.007. The procedures in patients who developed SCI took
longer (463.5 versus 307.2 minutes) and utilised more stents (4 versus 2).
Conclusion: SCI following thoracic and thoracoabdominal aortic en-
dovascular intervention is associated with the proportion of aorta covered.
The degree of risk varies between different types of procedure and this
should be carefully considered in both selection and consenting of patients.
Prognosis of Vascular Surgery Patients Using a Quantitative Assess-
ment of Troponin T Release: Is the Crystal Ball still Clear?
Winkel T.A., Schouten O., Hoeks S.E., Voûute M.T., Chonchol M., Goei
D., Flu W.-J., van Kuijk J.-P., Lindemans J., Verhagen H.J.M., Bax J.J.,
Poldermans D. Eur J Vasc Endovasc Surg 2010;40:742-9.
Background: Cardiac troponin T (cTnT) assays with increased sensi-
tivity might increase the number of positive tests. Using the area under the
curve (AUC) with serial sampling of cTnT an exact quantification of the
myocardial damage size can be made. We compared the prognosis of
vascular surgery patients with integrated cTnT–AUC values to continuous
and standard 12-lead electrocardiography (ECG) changes.
Methods: 513 Patients were monitored. cTnT sampling was per-
formed on postoperative days 1, 3, 7, 30 and/or at discharge or whenever
clinically indicated. If cTnT release occurred, daily measurements of cTnT
were performed, until baseline was achieved. CTnT–AUC was quantified
and divided in tertiles. All-cause mortality and cardiovascular events (cardiac
death and myocardial infarction) were noted during follow-up.
Results: 81/513 (16%) Patients had cTnT release. After adjustment
for gender, cardiac risk factors, and site and type of surgery, those in the
highest cTnT–AUC tertile were associated with a significantly worse cardio-
vascular outcome and long-term mortality (HR 20.2; 95% CI 10.2–40.0
and HR 4.0; 95% CI 2.0–7.8 respectively). Receiver operator analysis
showed that the best cut-off value for cTnT–AUC was0.01 days*ng m for
predicting long-term cardiovascular events and all-cause mortality.
Conclusion: In vascular surgery patients quantitative assessment of
cTnT strongly predicts long-term outcome.
The Efficacy of a New Stimulation Technology to Increase Venous
Flow and Prevent Venous Stasis
Griffin M., Nicolaides A.N., Bond D., Geroulakos G., Kalodiki E. Eur J Vasc
Endovasc Surg 2010;40:769-74.
Objectives: Electrical stimulation of calf muscles has been shown to be
effective in prevention of DVT. The aim was to determine: (a) dependence
of venous blood velocity and ejected volume on the rates of stimulated calf
contractions: (b) clinical factors affecting efficacy in healthy individuals.
Methods: The maximum intensity stimulus tolerated was applied to
calfs of 24 volunteers. In popliteal veins, Peak Systolic Velocities (PSV),
ejected volume per individual stimulus (Stroke Volume SV) and ejected
Total Volume Flow per minute (TVF) of expelled blood were determined
using ultrasound. Stimulation rates from 2 to 120 Beats Per Minute (bpm)
were applied.
Results: Mean baseline popliteal PSV was 10 cm/s. For stimulation
rates between 2 and 8 bpm, the PSV was 10 times higher and reached
96–105 cm/s. Stroke volume (SV) per individual stimulus decreased in a
similar fashion. With increasing rates of stimulation the TVF increased by a
factor of 12 times (from 20 ml/min to 240 ml/min).
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the calf muscle pump. Enhancements of popliteal blood velocity and volume
flow are key factors in the prevention of venous stasis and DVT. Further
studies are justified to determine the stimulation rates in those with a
compromised venous system.
Blocking the Saphenofemoral Junction During Ultrasound-Guided
Foam Sclerotherapy – Assessment of a Presumed Safety-measure
Procedure
Ceulen R.P.M., Jagtman E.A., Sommer A., Teule G.J.J., Schurink G.W.H.,
Kemerink G.J. Eur J Vasc Endovasc Surg 2010;40:775-9.
Objectives: Ultrasound-guided foam sclerotherapy (UGFS) is a tech-
nique in which a mixture of sclerosing drug and gas is used to treat varicose
veins. Several authors have demonstrated transient systemic effects after
UGFS. These effects are not well understood but probably originate from a
systemic distribution of the sclerosing foam. Therefore, safety measures have
been developed to prevent foam from flowing into the deep venous system.
The aim of the study is to evaluate whether blockage of the saphenofemoral
(SF) junction by either manual compression or surgical ligation prevents
microbubbles from leaking into the deep venous circulation.
Methods: To detect the distribution of microbubbles, radioactive
pertechnetate (99mTcO4) was added to the foam solution. Initially, in vitro
trials were performed in the laboratory to investigate the effect of 99mTc on
foam stability. The time taken for foam to liquefy was measured for foam
alone and for the mixture with 99mTc. In subsequent research, eight varicose
great saphenous veins (GSVs) were treated by UGFS. In three patients, this
treatment was preceded by surgical ligation of the SF junction. In three
patients, the groin was manually compressed during UGFS. In two patients,
UGFS was performed without compression of the groin.
Results: In vitro, 99mTc did not influence foam stability; after 2.6 min
all foam had reduced to liquid, regardless of whether 99mTc had been addedReaders can access EJVES articles at http://intl.e99mTc mixture injection. However, the decrease of radioactivity was slightly
reduced when compression or ligation of the SF junction was performed.
Conclusions: Blocking the SF junction during UGFS using either
manual compression or ligation does not prevent, but may reduce the flow of
foam into the femoral vein.
Healing and Recurrence Rates Following Ultrasound-guided Foam
Sclerotherapy of Superficial Venous Reflux in Patients with Chronic
Venous Ulceration
Pang K.H., Bate G.R., Darvall K.A.L., Adam D.J., Bradbury A.W. Eur J
Vasc Endovasc Surg 2010;40:793-8.
Objectives: To determine healing and recurrence rates following ul-
trasound-guided foam sclerotherapy (UGFS) of superficial venous reflux
(SVR) in patients with healed (clinical, etiologic, anatomic and pathophys-
iologic (CEAP) classification, C5) and open (C6) chronic venous ulceration
(CVU).
Methods: Between 1 March 2005 and 31 December 2009, 130
consecutive patients (132 limbs, 49 CEAP C5, 83 C6) of median age 70
(interquartile range (IQR) 56–76) years underwent UGFS as part of their
treatment for CVU.
Results: The median (IQR) follow-up time was 16 (12–32) months.
One C6 patient moved abroad 1 week after UGFS and was lost to follow-up.
Healing was observed in 67/82 (82%) remaining C6 patients at a median
(IQR) of 1 (1–2) month following their first UGFS treatment. In 49 limbs
originally treated for C5 disease, and in 67 limbs treated for C6 that healed
following UGFS, there were five recurrent ulcers during the follow-up
period, giving a 4.9% Kaplan–Meier estimate of recurrence at 2 years. In legs
treated for C6 and C5 disease, the median (IQR) ulcer-free periods were 22
(IQR 9–32) and 14 (IQR 8–36) months, respectively.
Discussion:Healing rates following UGFS for CVU are comparable to
those reported after surgery but recurrence may be lower. UGFS is a safe,or not. In vivo trials showed that all patients showed a decrease in the
cumulative amount of 99mTc detected in the GSV following polidocanol-
clinically effective and, thus, highly attractive minimally invasive alternative
to surgery in patients with C5 and C6 disease.lsevierhealth.com/journals/ejvs/default.cfm
